CHICAGO, January 11, 2022 / PRNewswire / – The draft ruling released today by the Centers for Medicare & Medicaid Services (CMS) is shocking discrimination against all people with Alzheimer’s disease, especially those already disproportionately affected by this deadly disease, including women, blacks and Hispanics.
With this approach, access to treatment would now only be available to a privileged few, those who have access to research institutions, exacerbating and creating new inequalities in health. In rendering its decision, CMS has the audacity to quote the Alzheimer’s Association Alzheimer’s disease facts and figures 2021 report on the challenges and obstacles faced by under-represented communities in participating in clinical trials, then do an about-face and propose to impose those same obstacles.
People living with Alzheimer’s disease deserve the same access to therapy as those living with other diseases such as cancer, heart disease and HIV / AIDS. To members of the Administration, treating people with Alzheimer’s disease differently from people with other diseases is simply unacceptable.
Critically, this draft decision is not about a treatment, but this class of potential future treatments targeting amyloid for the treatment of Alzheimer’s disease. This draft decision appears to be focused on individual treatment rather than class, which is not what CMS set out to do.
CMS should modify this draft decision. They must ensure equitable access to all who could benefit from the treatments approved by the FDA. The Alzheimer’s Association asks CMS not only to listen, but also to hear the needs of people with dementia and their caregivers.
The above can be attributed to Harry johns, CEO of the Alzheimer’s Association.
The Alzheimer’s Association is leading the way in ending Alzheimer’s disease and all other dementias – by accelerating global research, promoting risk reduction and early detection, and optimizing the quality of care and support . Our vision is a world without Alzheimer’s or any other dementia®. For more information visit www.alz.org or call the 24/7 helpline at 800.272.3900.
View original content to download multimedia:https://www.prnewswire.com/news-releases/alzheimers-association-statement-on-cms-draft-decision-301458975.html
SOURCE Alzheimer Association